MIRA Pharmaceuticals (NASDAQ:MIRA) Announces Earnings Results, Beats Estimates By $0.06 EPS

MIRA Pharmaceuticals (NASDAQ:MIRA) released its earnings results on Tuesday. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.06, FiscalAI reports.

MIRA Pharmaceuticals Trading Up 11.1%

NASDAQ MIRA traded up $0.11 during mid-day trading on Tuesday, hitting $1.07. The company’s stock had a trading volume of 90,832 shares, compared to its average volume of 153,211. The firm has a market capitalization of $44.81 million, a price-to-earnings ratio of -0.70 and a beta of 1.78. The company’s 50 day simple moving average is $1.20 and its 200 day simple moving average is $1.36. MIRA Pharmaceuticals has a twelve month low of $0.73 and a twelve month high of $2.45.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its holdings in shares of MIRA Pharmaceuticals by 100.0% during the fourth quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock valued at $412,000 after buying an additional 136,438 shares during the last quarter. Two Sigma Investments LP lifted its position in MIRA Pharmaceuticals by 129.8% in the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after acquiring an additional 25,816 shares in the last quarter. XTX Topco Ltd bought a new position in MIRA Pharmaceuticals in the 2nd quarter valued at about $26,000. Finally, Creative Planning acquired a new position in MIRA Pharmaceuticals during the 2nd quarter valued at about $27,000. 35.16% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on MIRA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research note on Friday. Rodman & Renshaw started coverage on MIRA Pharmaceuticals in a research note on Tuesday, January 13th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.